The phosphoinositide 3-kinase (PI3K) signaling cascade is a key mediator of cellular growth, survival and metabolism and is frequently subverted in human cancer. The gene encoding for the alpha catalytic subunit of PI3K (PIK3CA) is mutated and/or amplified in B30% of breast cancers. Mutations in either the kinase domain (H1047R) or the helical domain (E545K) are most common and result in a constitutively active enzyme with oncogenic capacity. PIK3CA
INTRODUCTION
The phosphoinositide 3-kinase (PI3K) pathway is a key regulator of cell growth, proliferation, metabolism and survival and is often found to be hyperactivated in human cancer. 1, 2 The most common aberrations of the PI3K pathway include mutation and/or amplification of PIK3CA, [3] [4] [5] [6] [7] the gene encoding the alpha catalytic subunit of the kinase (p110a), loss of expression of the PTEN phosphatase that reverses PI3K action, activation downstream of oncogenic receptor tyrosine kinases and mutation/amplification of Akt. 1 Hyperactivation of the PI3K pathway increases tumorigenicity by reducing cell death and increasing cell proliferation, migration, invasion, metabolism and angiogenesis. 1, 2 It also enhances resistance to chemotherapy. 8 The majority of mutations in PIK3CA occur at two 'hotspots' within the kinase (H1047R) and helical domains (E542K and E545K) of p110a. 6, 9 These mutations lead to a constitutively active enzyme, transform cells in vitro, and enhance tumorigenicity in xenograft models. [10] [11] [12] [13] Notably, different mechanisms underlie the gain-of-function activities of helical-and kinase domain mutants. While PIK3CA E545K is independent of binding to the adaptor molecule p85 but requires interaction with Ras-GTP, the PIK3CA H1047R mutant is highly dependent on p85 for its oncogenic capacity but independent of Ras-GTP.
14 PIK3CA gain-of-function mutations are found in B30% of human breast cancers 3, 6, [15] [16] [17] and most likely occur at an early stage of breast carcinoma development, as suggested by the similar mutation frequencies in PIK3CA found in pure ductal carcinoma in situ, ductal carcinoma in situ adjacent to invasive ductal carcinoma, and invasive ductal carcinoma. 18 Evaluation of the clinical outcome of genomic alterations in PIK3CA has produced contradictory results. 15, 19, 20 However, these studies showed that alterations in different exons of PIK3CA have varying impacts on tumor development and progression and, therefore, differ in prognostic value. For example, both mutations are associated with lower grade and hormone receptor-positive tumors, but PIK3CA H1047R mutants are strongly associated with lymph-node negativity and PIK3CA E545K mutants with older age at diagnosis, indicating the different oncogenic potentials of the H1047R and E545K mutations. 19 This is further supported by the different frequencies of E545K (B6%) and H1047R (B15%) mutations in breast cancer. 17, 21 In vivo transplantation assays have demonstrated PIK3CA
H1047R to be more potent in inducing tumors 10 but another study found no trend, 12 and the exact impact of these mutations on breast cancer has remained controversial.
We and others have reported that expression of PIK3CA H1047R in the mammary gland induces heterogeneous tumors. [22] [23] [24] [25] To determine which PIK3CA mutant shows higher oncogenic activity in vivo, we generated a novel conditional mouse model expressing PIK3CA
E545K . We have demonstrated that PIK3CA
E545K
induces heterogeneous mammary tumors that express basal and luminal markers but is a less potent oncogene in vivo than PIK3CA H1047R .
RESULTS AND DISCUSSION
Expression of PIK3CA E545K but not wild-type PIK3CA induces mammary tumors We and others have shown that PIK3CA H1047R induces mouse mammary carcinomas. [22] [23] [24] [25] To test whether overexpression of wild-type human PIK3CA (PIK3CA wt ) or PIK3CA E545K also induces mammary tumors, we generated novel transgenic mice that conditionally express PIK3CA wt or PIK3CA E545K (Figure 1a ). To achieve equivalent transgene expression, we integrated PIK3CA wt or PIK3CA
E545K into the ROSA26 locus using recombinasemediated cassette exchange. 26 Correct integration of the target cassettes was confirmed in the resulting PIK3CA wt and PIK3CA
E545K
lines (Figure 1b, left) . PIK3CA wt and PIK3CA E545K animals were then crossed to WAPiCre mice in which expression of recombinase Cre is controlled by the whey acidic protein (WAP) promoter, which is mainly active in secretory mammary epithelial cells, and expression of the transgenes confirmed (Figure 1b, right) . [27] [28] [29] [30] This enabled us to directly compare the kinetics of tumor onset in PIK3CA wt and PIK3CA E545K mice, and the previously reported WAPiCre PIK3CA H1047R mice. 22 The resulting bi-transgenic WAPiCre PIK3CA wt and WAPiCre PIK3CA E545K female mice were impregnated to achieve maximal Cre-mediated recombination and the pups removed 1 day after delivery. All WAPiCre PIK3CA E545K mice developed mammary tumors on average 80 ( ± 10) days after delivery, whereas parous WAPiCre PIK3CA wt mice did not form tumors within 520 days ( Figure 1c ). This indicates that overexpression of wild-type PIK3CA itself is insufficient to induce mammary tumors. Of note, the latency to tumor onset in WAPiCre PIK3CA E545K animals was significantly longer than that observed previously for WAPiCre PIK3CA H1047R mice (36 (±4.9) days). 22 We also crossed PIK3CA E545K and PIK3CA H1047R lines to CAGs-CreERT2 mice that express a tamoxifen-inducible Cre/ estrogen receptor (ER) fusion protein under the control of a modified b-actin promoter; this results in the expression of Cre-ER in virtually all cells. Unexpectedly, bi-transgenic CAGs-Cre PIK3CA
and PIK3CA H1047R mice died by the age of 4 months even when no tamoxifen was administered. Although we were unable to identify the exact cause of death, we concluded that leakiness of the CAGsCreERT2 system caused premature and deleterious PIK3CA E545K or PIK3CA H1047R expression in various tissues of these mice (DSM and MB-A, unpublished observations).
To compare the tumor-initiating potential of the two different PIK3CA mutants, we then transplanted pieces of mammary gland tissue from CAGs-CreERT2 PIK3CA E545K or PIK3CA H1047R donor mice previously treated with tamoxifen into cleared fat pads of Balb/c mice. The mammary glands reconstituted by either CAGs-CreERT2 PIK3CA E545K or PIK3CA H1047R -derived epithelium were hyperplastic (data not shown) and eventually formed tumors after 229 ( ± 17, PIK3CA H1047R ) and 336 days ( ± 20, PIK3CA E545K ), respectively ( Figure 1d ). As observed in the WAPiCre mouse cohorts, PIK3CA
E545K was significantly less potent than PIK3CA H1047R in the induction of mammary carcinomas, which is a possible explanation for the lower frequency of E542K/E545K mutations in human breast cancer. Figures 2a and b) , which was also the most common histotype formed by WAPiCre PIK3CA H1047R mice (54.6%). 22 Adenocarcinomas (23.3%) and carcinomas (6.7%) were also observed albeit at lower frequencies (Figures 2a and b ). An adenocarcinoma with squamous metaplasia (3.3%), an adenomyoepithelioma (3.3%) and spindle cell tumor (3.3%) were observed in one tumor only (Figures 2a and b) . The low frequency of adenomyoepithelioma in WAPiCre PIK3CA E545K mice is in stark contrast to the WAPiCre PIK3CA H1047R animals, in which adenomyoepitheliomas accounted for B23% of the tumors. 22 A further discrepancy between mice expressing PIK3CA E545K or PIK3CA H1047R was the complete absence of diffuse and invasive adenocarcinomatosis in WAPiCre PIK3CA E545K -derived glands, a histological feature that was displayed by all tumor-surrounding tissue in WAPiCre PIK3CA H1047R mice. 22 The PIK3CA E545K -induced tumors were stained for luminal cytokeratin 18 (K18), basal/myoepithelial cytokeratin 14 (K14), and myoepithelial a-smooth muscle actin (a-SMA) markers. The most frequent histotypes, adenosquamous carcinoma and adenocarcinoma, were positive for both luminal K18 and basal K14 (Figure 2c ). In tumors of the adenosquamous carcinoma type, the relative tumor areas positive for K18 and K14 were B35% and B39%, respectively (Figure 2d ) and largely negative for a-SMA (o1%) (Figure 2d ). WAPiCre PIK3CA E545K -evoked adenosquamous carcinomas also stained positive for ER (B8% of the tumor cells) and displayed a high proportion of Ki-67-positive cells (B35%) (Figures 2c and d) . The relative tumor areas and cells positive for K14, K18, a-SMA, ER and Ki-67 were very similar to those observed in PIK3CA
H1047R -driven adenosquamous carcinomas. 22 However, the number of apoptotic cells staining positively for cleaved 
E545K -evoked adenosquamous carcinomas (B7%) (Figures 2c and d) than those derived from WAPiCre H1047R mice (B1%), 22 indicating that PIK3CA H1047R is a more potent suppressor of apoptosis than PIK3CA E545K in mammary tumors. In summary, both PIK3CA E545K and PIK3CA H1047R produced K14/ K18-positive tumors of various histotypes, with the adenosquamous carcinoma type being the most common in both transgenic models. However, differences between the mouse models included low abundance of adenomyoepitheliomas and the absence of adenocarcinomatosis in WAPiCre PIK3CA E545K mice. The variations in tumor histotypes and the discrepancy in tumor latency in WAPiCre PIK3CA E545K and PIK3CA H1047R mice suggest that different mechanisms underlie tumor initiation by these mutants. To gain a mechanistic insight that might explain these differences, we investigated whether pregnancy accelerates tumor onset in WAPiCre PIK3CA
E545K as it does in WAPiCre PIK3CA H1047R mice. 22 Pregnancy accelerated tumor onset in WAPiCre PIK3CA E545K mice, reducing latency from 228±15 days in nulliparous to 165 ± 10 days in parous mice (Figure 3a) . Interestingly, pregnancy appeared to accentuate the difference in tumor latency between WAPiCre PIK3CA E545K and PIK3CA H1047R mice, shown by 32 days difference in nulliparous vs 48 days difference in parous mice (Figure 3a) . 22 We showed previously that a pregnancy-induced delay in mammary gland involution accounts, at least in part, for accelerated tumor kinetics in parous vs nulliparous PIK3CA H1047R mice. 22 Thus, we hypothesized here that the longer tumor latency of parous WAPiCre PIK3CA E545K compared with parous WAPiCre PIK3CA H1047R animals is the result of a less-pronounced involution delay. Comparison of WAPiCre PIK3CA
E545K and WAPiCre PIK3CA H1047R glands 15 days after weaning revealed a dramatic delay in involution compared with control animals (Figure 3b) . The relative gland area occupied by epithelial cells was the same in WAPiCre PIK3CA E545K and PIK3CA H1047R mice and significantly larger than in WAPiCre control glands (Figure 3c) . Similarly, there was no difference in the number of apoptotic or proliferating cells in glands expressing either of the PIK3CA mutations (Figure 3d) . Interestingly, glands from WAPiCre PIK3CA wt mice, which did not form tumors, displayed normal involution and numbers of apoptotic and proliferating cells similar to the controls (Figure 3) , indicating that the delay in involution is caused by mutant PIK3CA rather than by mice developed palpable tumors on average after 165 ( ± 10) days whereas nulliparous mice developed tumors on average after 228 ( ± 15) days (PIK3CA E545K ); P ¼ 0.0023. (b) Representative images of whole mount (top panels), magnification of whole mount (center panels) and H&E (lower panels) staining of involuting glands from WAPiCre control, WAPiCre PIK3CA wt , WAPiCre PIK3CA E545K and WAPiCre PIK3CA H1047R mice as indicated. The glands were isolated 15 days after removal of the pups. Scale bar ¼ 1 cm (whole mounts). Scale bar ¼ 100 mm (H&E sections). (c) Bar graph showing relative epithelium to total gland area of involution at day 15 in whole mounts prepared from WAPiCre control (n ¼ 3), WAPiCre PIK3CA wt (n ¼ 4), WAPiCre PIK3CA E545K (n ¼ 4) and WAPiCre PIK3CA H1047R (n ¼ 2 H1047R transgene expression caused a dramatic but comparable delay in involution and, therefore, involution does not explain the different tumor kinetics observed in parous vs nulliparous mice expressing these mutations.
Comparison of lysates from WAPiCre PIK3CA E545K -and WAPiCre PIK3CA H1047R -derived mammary glands and tumors showed equal expression of p110a in tumors from both transgenic models (Figure 4a ). Despite the enhanced oncogenic potential of the PIK3CA H1047R mutant, no differences in activation of the PI3K/Akt or the Erk pathways were observed in the tumors (Figure 4a ). Similarly, a more detailed analysis of Akt1 and Akt2 isoform-specific phosphorylation revealed no difference between PIK3CA E545K -and WAPiCre PIK3CA H1047R -induced signaling (Figure 4b) . Conceivably, by the time mammary tumors were established, numerous secondary mutations had resulted in a tumor heterogeneity that compromises the detection of potentially subtle differences in oncogenic signaling induced by either PIK3CA mutant. To circumvent this, we investigated molecular signaling events in mutant PIK3CA-expressing epithelial cells at an early pre-neoplastic stage. Protein lysates from mammary glands isolated 12 h after the onset of involution revealed increased activation of Akt and decreased phosphorylation of the signal transducer and activator of transcription (STAT) 3 in mutant relative to control glands. Notably, both hyperactivation of Akt and hypoactivation of STAT3 were more pronounced in PIK3CA H1047R than in PIK3CA E545K glands (for pAkt P ¼ 2.5 Â 10 À 4 ; for pSTAT3 P ¼ 0.047) (Figure 4c ).
In summary, we found that overexpression of PIK3CA E545K in a transgenic mouse model potently induces heterogeneous mammary tumors whereas overexpression of wild-type PIK3CA does not. Notably, although PIK3CA E545K evokes tumors with 100% penetrance it is a weaker inducer of mammary tumors than PIK3CA H1047R in two independent mouse models in which mutant PIK3CA is either driven by the WAP or by the CAGs promoter. This may explain the lower frequency of helical vs kinase domain mutations in human breast cancer. 13 We found differences in Akt and STAT3 activation in preneoplastic mammary glands from PIK3CA E545K and PIK3CA
H1047R
transgenic mice that may explain the longer tumor latency observed in WAPiCre PIK3CA E545K compared with WAPiCre PIK3CA H1047R mice. The novel transgenic mouse models reported here provide excellent tools to further dissect the activities of different PIK3CA mutants in tumor initiation in vivo and to investigate drug responses to the ever-increasing number of PI3K pathway inhibitors.
MATERIALS AND METHODS

Transgenic mice
We constructed a vector with a transcriptional STOP sequence flanked by loxP sites upstream of the 5'-terminally HA-tagged human PIK3CA cDNA (Addgene, Cambridge, MA, USA) and an IRES2-EGFP reporter element (pIRES2-EGFP vector; Clontech, Mountain View, CA, USA). The resulting construct was introduced into the modified Rosa26 locus of Balb/c mouse embryonic stem cells by recombinase-mediated cassette exchange as described earlier. 22 Chimeric mice were backcrossed to Balb/c mice and transgenic mice identified by genotyping. ; for pSTAT3 P ¼ 0.047; for p110a P ¼ 0.7. NS ¼ not significant.
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Immunoblotting Protein lysates were extracted from inguinal mammary glands or tumors using LB buffer (50 mM Tris-HCl pH8, 150 mM NaCl, 1% NP-40) supplemented with 0.5 mM sodium orthovanadate. Anti-p110a, anti-pAKT (Ser473), anti-Akt, anti-pERK1/2 (Thr202/Tyr204), anti-ERK1/2, anti-pS6 (Ser235/236), anti-S6, antiAkt1, anti-Akt2, anti-pSTAT3 (Tyr705) and anti-STAT3 antibodies were purchased from Cell Signaling Technology, Danvers, MA, USA.
Immunohistochemistry
The following antibodies were used: K14 (Thermo Scientific, , Waltham, MA, USA, RB-9020, 1:100), K18 (Fitzgerald, Acton, MA, USA, #GP11, 1 : 200), ER (Santa Cruz, , Dallas, TX, USA, SC-542, 1:1000), a-SMA (Thermo Scientific, RB-9010, 1:500), cleaved caspase-3 (Cell Signaling, #9661, 1:100) Ki-67 (Thermo Scientific, RB-9106, 1:50).
Southern blotting
Genomic DNA from mouse tails was digested with 8 U of AvrII enzyme (New England BioLabs (NEB), Ipswich, MA, USA) and separated on a 1% agarose gel. A DIG-labeled DNA probe targeting the neomycin resistance cassette was amplified using the PCR DIG Probe Synthesis Kit (Roche, Basel, Switzerland) and the primers 5'-ATGGGATCGGCCATTGAACAAGAT-3' and 5'-CGGCCATTTTCCACCATGATAT-3'.
